3 studies published at the annual meeting show that a new mechanism of antiviral drugs - the cell inhibitors may provide more options for he
3 studies published at the annual meeting show that a new mechanism of antiviral drugs - the cell inhibitors may provide more options for hepatitis B treatment.
The first study from Germany, showed that in hepatitis B virus (HBV) infection before and after the synthesis of antilipid polysaccharide peptide (SALP) in treatment of liver cells in vitro, infection is inhibited, in a dose-dependent manner. When the drug concentration was 0.5 ~ 2 g/ml, the level of HBV infection markers could be reduced by 50%. When the drug concentration was from 4 to 5 g/ml, the drug concentration could be reduced by 90%. In addition, SALP also showed activity against other viruses, such as herpes simplex virus, human immunodeficiency virus (HIV) or bacteria (such as pneumococcal).
In another two studies, the researchers used HBV and chronic hepatitis D virus (HDV) infection of chimeric mice pre clinical evaluation, HBV entry inhibitors myrcludex-B can completely block the spread of HBV in the cells, and prevent human liver cells infected with HDV.
No.1 Hospital of Peking University professor Wang Guiqiang comments
To enter the target cells and replicate in them is the basis of virus pathogenicity. Viral entry is usually mediated by cell surface specific molecules (receptors) that enter the cell directly through the plasma membrane or endocytosis. Aiming at this characteristic, the research and development of drugs to inhibit viral entry into cells is an important part in the field of antiviral therapy. The mechanism of HBV entry into hepatocytes has not been elucidated, which leads to the limitation of drug development for HBV cells.
The above 3 studies provide a new idea for the treatment of hepatitis B, but the effectiveness and safety of the patients need to be further studied.